Profile data is unavailable for this security.
About the company
BioArctic AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of treatments, which aim at diseases that affect the central nervous system (CNS). Its therapeutic areas encompass neurodegenerative disorders, Alzheimer's disease, Parkinson's disease, complete spinal cord injury, as well as other CNS disorders. The Company owns a technology platform, which develops a range of therapeutic monoclonal antibodies. The Company's pipeline includes product candidates in various clinical phases, such as BAN2401, AE1501, BAN0805, imaging and biochemical biomarkers, BBB-technology and SC0806. The Company also operates through SpineMedical AB.
- Revenue in SEK (TTM)299.35m
- Net income in SEK-88.28m
- Incorporated2000
- Employees96.00
- LocationBioArctic ABWarfvinges vag 35STOCKHOLM 112 51SwedenSWE
- Phone+46 86956930
- Fax+46 86956939
- Websitehttps://www.bioarctic.se/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Philogen SpA | 262.68m | -69.97m | 6.64bn | 160.00 | -- | 8.90 | -- | 25.29 | -0.1551 | -0.1551 | 0.5747 | 2.25 | 0.1887 | 6.65 | 7.95 | 144,562.50 | -5.03 | -7.32 | -5.56 | -8.36 | 40.04 | 32.04 | -26.64 | -58.66 | 6.84 | -- | 0.1414 | -- | -2.46 | 10.80 | -14.60 | -- | 51.78 | -- |
| Abivax SA | 0.00 | -2.01bn | 7.30bn | 62.00 | -- | 5.05 | -- | -- | -3.20 | -3.20 | 0.00 | 2.01 | 0.00 | -- | -- | 0.00 | -77.89 | -65.49 | -107.73 | -97.67 | -- | -- | -- | -- | -- | -110.67 | 0.4334 | -- | -- | -- | -111.52 | -- | -19.06 | -- |
| Basilea Pharmaceutica AG Allschwil | 1.78bn | -7.80m | 7.42bn | 156.00 | -- | 33.97 | 539.75 | 4.16 | -0.2814 | -0.2814 | 11.54 | 1.38 | 0.7118 | 1.22 | 4.40 | 1,013,755.00 | -0.3114 | -1.86 | -0.4156 | -2.99 | 76.57 | 83.45 | -0.4375 | -2.99 | 3.27 | -1.38 | 0.8508 | -- | 6.68 | 3.53 | -13.96 | -- | 11.17 | -- |
| Kuros Biosciences AG | 628.79m | -106.34m | 9.06bn | 80.00 | -- | 12.37 | -- | 14.41 | -0.2295 | -0.2295 | 1.73 | 1.64 | 0.6755 | 1.95 | 7.89 | 656,775.00 | -11.42 | -13.47 | -13.53 | -14.84 | 79.13 | 78.73 | -16.91 | -81.48 | 2.17 | -- | 0.0847 | -- | 86.61 | 115.93 | 5.95 | -- | -13.21 | -- |
| Formycon AG | 690.49m | 725.66m | 9.73bn | 239.00 | 12.13 | 1.49 | 12.98 | 14.08 | 4.00 | 4.00 | 3.64 | 32.64 | 0.0654 | 34.46 | 1.55 | 255,462.20 | 6.87 | 5.87 | 7.37 | 6.33 | 12.46 | 28.54 | 105.09 | 39.76 | 2.06 | -- | 0.0185 | 0.00 | 82.83 | 12.47 | 110.59 | 60.58 | 81.87 | -- |
| Evotec SE | 8.95bn | -1.94bn | 12.11bn | 5.02k | -- | 1.05 | -- | 1.35 | -0.9634 | -0.9634 | 4.45 | 5.70 | 0.3667 | 18.94 | 4.10 | 155,787.40 | -7.94 | -0.0064 | -9.88 | -0.0076 | 15.98 | 24.51 | -21.65 | -0.0178 | 1.73 | -1.70 | 0.3189 | 0.00 | 3.99 | 15.79 | 52.23 | -- | 50.62 | -- |
| BioArctic AB | 299.35m | -88.28m | 12.43bn | 96.00 | -- | 16.03 | 263.61 | 41.51 | -0.9972 | -0.9972 | 3.39 | 10.52 | 0.2699 | -- | -- | 3,401,659.00 | -7.96 | 2.24 | -8.90 | 2.56 | 88.22 | 86.52 | -29.49 | 9.76 | -- | -- | 0.0604 | 0.00 | 169.83 | -2.91 | 2,150.71 | -9.69 | 11.83 | -- |
| Gubra A/S | 312.16m | -67.80m | 12.60bn | 219.00 | -- | 17.19 | -- | 40.35 | -2.91 | -2.91 | 13.51 | 29.44 | -- | -- | -- | 936,095.90 | -- | -- | -- | -- | 56.06 | -- | -21.72 | -- | -- | -- | 0.1296 | -- | 2.82 | -- | -1,133.04 | -- | -- | -- |
| Genus plc | 9.06bn | 107.07m | 16.52bn | 3.48k | 155.62 | 2.22 | 24.68 | 1.82 | 0.1186 | 0.1186 | 10.14 | 8.30 | 0.6569 | -- | 5.37 | -- | 0.2357 | 3.30 | 0.2742 | 3.87 | -- | -- | 0.3589 | 4.98 | 1.42 | 279.50 | 0.3487 | 62.72 | -3.03 | 6.48 | -76.28 | 0.2551 | -2.68 | 2.93 |
Data as of Sep 20 2024. Currency figures normalised to BioArctic AB's reporting currency: Swedish Krona SEK
30.79%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fj�rde AP-fondenas of 24 Jan 2024 | 4.75m | 6.45% |
| Tredje AP-fondenas of 31 Dec 2023 | 3.35m | 4.55% |
| Swedbank Robur Fonder ABas of 31 Dec 2023 | 3.13m | 4.25% |
| RA Capital Management LPas of 31 Dec 2023 | 3.12m | 4.23% |
| Handelsbanken Fonder ABas of 31 Aug 2024 | 2.18m | 2.96% |
| Nordea Investment Management ABas of 31 Jul 2024 | 2.06m | 2.79% |
| The Vanguard Group, Inc.as of 04 Sep 2024 | 1.23m | 1.67% |
| SEB Investment Management ABas of 30 Aug 2024 | 1.07m | 1.45% |
| Lannebo Fonder ABas of 31 Dec 2023 | 944.00k | 1.28% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 848.95k | 1.15% |
More ▼
Data from 31 Dec 2023 - 31 Jul 2024Source: FactSet Research Systems Inc.
